Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 16/20 | 0.54 |
| ▸ | MTOR | P42345 | 12/20 | 0.45 |
| ▸ | RICTOR | Q6R327 | 6/20 | 0.44 |
| ▸ | RPTOR | Q8N122 | 6/20 | 0.44 |
| ▸ | MAPKAP1 | Q9BPZ7 | 6/20 | 0.44 |
| ▸ | MLST8 | Q9BVC4 | 6/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27430515 | 0.93 | PIK3CA (0.63) | PIK3CAMTORRICTORRPTORMAPKAP1 | |
| SCHEMBL27428932 | 0.90 | PIK3CA (0.52) | PIK3CAMTORRICTORRPTORMAPKAP1 | |
| SCHEMBL27428898 | 0.86 | PIK3CA (0.57) | PIK3CAMTORRICTORRPTORMAPKAP1 | |
| SCHEMBL27430594 | 0.84 | PIK3CA (0.61) | PIK3CAMTORRICTORRPTORMAPKAP1 | |
| SCHEMBL27428902 | 0.84 | PIK3CA (0.58) | PIK3CAMTORRICTORRPTORMAPKAP1 | |
| SCHEMBL27428891 | 0.82 | PIK3CA (0.64) | PIK3CAMTORRICTORRPTORMAPKAP1 | |
| SCHEMBL27429151 | 0.82 | PIK3CA (0.81) | PIK3CAMTORRICTORRPTORMAPKAP1 | |
| SCHEMBL27428905 | 0.81 | PIK3CA (0.69) | PIK3CAMTORRICTORRPTORMAPKAP1 | |
| SCHEMBL27430485 | 0.80 | PIK3CA (0.67) | PIK3CAMTORRICTORRPTORMAPKAP1 | |
| SCHEMBL27428896 | 0.79 | PIK3CA (0.79) | PIK3CAMTORRICTORRPTORMAPKAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217960-A1 | TRIAZINE DERIVATIVE AS COVALENT INHIBITORS OF PI3K | UNIVERSITÄT BASEL (CH) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217960-A1 | TRIAZINE DERIVATIVE AS COVALENT INHIBITORS OF PI3K | PIK3R5, PIK3R1, PIK3R2 | PIK3CA 12/4885MTOR 61/4885RICTOR 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.